AAHRPP Accredits First Organizations in Europe
Four Others, in U.S. and China, Also Earn Accreditation
WASHINGTON, D.C.âThe Association for the Accreditation of Human Research Protection Programs today announced that it has accredited six more research organizations, including its first two in Europe. Both are in Belgium.
Three U.S. organizations and a hospital in China also are among the latest to earn AAHRPP accreditation.
The newly accredited organizations are:
- Children’s Mercy Hospital, Kansas City, Missouri
- Cliniques Universitaires de Bruxelles- Hôpital Erasme, Brussels, Belgium
- Cliniques Universitaires Saint-Luc, Brussels, Belgium
- Renal Research Institute, LLC, New York, New York
- Texas Tech University Health Sciences Center, Lubbock, Texas
- The Third Xiangya Hospital of Central South University, Changsha, Hunan Province, China
“These latest accreditations expand AAHRPP’s influence in yet another key region for clinical research,” AAHRPP President and CEO Elyse I. Summers said. “With accredited organizations in Asia, Europe, Latin America and North America, we are strengthening protections for research participants around the globe and across all sectors of the research enterprise.”
AAHRPP-accredited organizations include universities, academic medical centers, community and specialty hospitals, independent institutional review boards, contract research organizations, dedicated research sites, research sponsors, and public health departments.
To earn AAHRPP accreditation, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to high standards for research. In today’s global, collaborative research enterprise, organizations increasingly rely on AAHRPP accreditation status to help identify trusted research partners.
To date, AAHRPP has accredited more than 215 organizations in 46 states, Belgium, Canada, China, India, Mexico, Republic of Korea, Saudi Arabia, Singapore, Taiwan, and Thailand. All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 60 percent of U.S. research-intensive universities and over 65 percent of U.S. medical schools are either AAHRPP accredited or have begun the accreditation process. The National Institutes of Health, the world’s largest public funder of research, has earned accreditation, as has Pfizer, Inc., the largest industry sponsor of clinical research.
About AAHRPP: A nonprofit organization, AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the U.S. government. To learn more, visit www.aahrpp.org.
###
FOR MORE INFORMATION CONTACT:
Sarah Kiskaddon Director, Global Development and Public Affairs
skiskaddon@aahrpp.org
(202) 783-1112
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
